<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">98903</article-id><article-id pub-id-type="doi">10.7554/eLife.98903</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.98903.4</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Phosphodiesterase 1A physically interacts with YTHDF2 and reinforces the progression of non-small cell lung cancer</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhang</surname><given-names>Chong</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8113-5585</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhang</surname><given-names>Zuoyan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0883-6016</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Yueyi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0008-3717-3884</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wu</surname><given-names>Yuchen</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Kaizhi</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Zhidi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0225-2028</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Manman</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0002-0235-143X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wang</surname><given-names>Jian</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0005-0457-9325</contrib-id><email>2538765918@qq.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhang</surname><given-names>Xuesen</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0007-7758-252X</contrib-id><email>xuesenz@163.com</email><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Li</surname><given-names>Yangling</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4461-478X</contrib-id><email>liyangling1215@163.com</email><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05v58y004</institution-id><institution>Department of Oncology, Shangyu People's Hospital of Shaoxing</institution></institution-wrap><addr-line><named-content content-type="city">Shaoxing</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01wck0s05</institution-id><institution>Department of Pharmacy, School of Medicine, Hangzhou City University</institution></institution-wrap><addr-line><named-content content-type="city">Hangzhou</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution>Department of Pharmacy, The Affiliated Hospital of Northwest University</institution><addr-line><named-content content-type="city">Shanxi</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05pkzpg75</institution-id><institution>Department of Pharmacy, Ningbo First Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Ningbo</named-content></addr-line><country>China</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00rd5t069</institution-id><institution>Department of Clinical Medicine, The First School of Medicine, Wenzhou Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Wenzhou</named-content></addr-line><country>China</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00a2xv884</institution-id><institution>College of Pharmaceutical Sciences, Zhejiang University</institution></institution-wrap><addr-line><named-content content-type="city">Hangzhou</named-content></addr-line><country>China</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00a2xv884</institution-id><institution>Department of Pharmacy, Zhejiang University of Technology</institution></institution-wrap><addr-line><named-content content-type="city">Hangzhou</named-content></addr-line><country>China</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01wck0s05</institution-id><institution>Hangzhou Lin’an Traditional Chinese Medicine Hospital , Affiliated Hospital, Hangzhou City University</institution></institution-wrap><addr-line><named-content content-type="city">Hangzhou</named-content></addr-line><country>China</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05hfa4n20</institution-id><institution>Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University</institution></institution-wrap><addr-line><named-content content-type="city">Hangzhou</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Evans</surname><given-names>Rachel</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220mzb33</institution-id><institution>King's College London</institution></institution-wrap><country>United Kingdom</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>White</surname><given-names>Richard M</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>24</day><month>07</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP98903</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-05-21"><day>21</day><month>05</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-05-23"><day>23</day><month>05</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.05.21.595220"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-10-15"><day>15</day><month>10</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.98903.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-03-03"><day>03</day><month>03</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.98903.2"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-05-22"><day>22</day><month>05</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.98903.3"/></event></pub-history><permissions><copyright-statement>© 2024, Zhang, Zhang et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Zhang, Zhang et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-98903-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-98903-figures-v1.pdf"/><abstract><p>Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer, and the prognosis is poor due to distant metastasis. Thus, there is an urgent need to discover novel therapeutic targets and strategies to overcome metastasis. A series of in vitro and in vivo phenotype experiments were performed to investigate the role of phosphodiesterase 1A (PDE1A) in NSCLC. The RNA binding protein immunoprecipitation (RIP) assay, messenger RNA (mRNA) stability assay, and LC-MS/MS were performed to investigate the molecular mechanisms of PDE1A in NSCLC progression. PDE1A has been shown to promote metastasis and epithelial-mesenchymal transition (EMT) progression of NSCLC. In addition, NSCLC cells overexpressing PDE1A promoted angiogenesis by regulating exosome release. IL-6/JAK/STAT3 signaling pathway was highly enriched in PDE1A-coexpressed genes, and PDE1A promoted NSCLC metastasis by activating the STAT3 pathway. GO enrichment analysis of PDE1A-interacting genes showed that PDE1A might interact with YTHDF2 and participate in m6A-containing RNA binding. The binding between PDE1A and YTHDF2 was verified, and PDE1A regulated the STAT3 pathway by interacting with YTHDF2. The mechanism of the YTHDF2/PDE1A complex in regulating the STAT3 pathway was predicted by overlapping YTHDF2-interacting RNAs and genes coexpressed with YTHDF2 and STAT3. The interactions between YTHDF2 and target mRNAs were predicted, and there were three predicted targets of YTHDF2 with high scores: NRF2, SOCS2, and MET. Indeed, PDE1A interacted with YTHDF2, destabilized SOCS2, and activated the STAT3 pathway. Mechanistic data uncover a novel PDE1A/YTHDF2/STAT3 axis driving NSCLC metastasis and suggest potential therapeutic strategies for metastatic disease.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>PDE1A</kwd><kwd>metastasis</kwd><kwd>YTHDF2</kwd><kwd>NSCLC</kwd><kwd>STAT3</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Huadong Medicine JointFunds of the Zhejiang Provincial Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>LHDMY22H160001</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Chong</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007834</institution-id><institution>Natural Science Foundation of Ningbo City</institution></institution-wrap></funding-source><award-id>2022J206</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Zuoyan</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82273352</award-id><principal-award-recipient><name><surname>Li</surname><given-names>Yangling</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>Xian Health Commission</institution></institution-wrap></funding-source><award-id>Youth Incubation Project 2024qn01</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Zuoyan</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>Scientific Research Foundation of Hangzhou City College</institution></institution-wrap></funding-source><award-id>X-202305</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Chong</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>National College Student Innovation and Entrepreneurship Project</institution></institution-wrap></funding-source><award-id>202313021036</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Zuoyan</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution>Zhejiang Provincial Medical and Health Technology Project</institution></institution-wrap></funding-source><award-id>2025KY391</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Jian</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Uncovering a novel PDE1A/YTHDF2/STAT3 pathway in non-small cell lung cancer (NSCLC) progression also provides therapeutic strategies for treating NSCLC patients with metastasis.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer-related mortality worldwide (<xref ref-type="bibr" rid="bib31">Thai et al., 2021</xref>). Non-small cell lung cancer (NSCLC) represents approximately 85% of lung cancers and is the most common subtype of lung cancer (<xref ref-type="bibr" rid="bib2">Alduais et al., 2023</xref>). Despite rapid advances in the clinical treatment of NSCLC in recent years, the prognosis of NSCLC patients is still poor due to recurrence and distant metastasis (<xref ref-type="bibr" rid="bib35">Xia et al., 2021</xref>). However, the mechanism of NSCLC metastasis is still poorly understood.</p><p>Phosphodiesterases (PDEs) are a class of enzymes that hydrolyze cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), reducing the signaling of these important intracellular second messengers (<xref ref-type="bibr" rid="bib10">Delhaye and Bardoni, 2021</xref>). PDEs consist of 11 family members, and each family member contains multiple subtypes (<xref ref-type="bibr" rid="bib26">Peng et al., 2018</xref>). PDEs are being pursued as therapeutic targets in multiple diseases, including the cardiovascular system, metabolism, pulmonary system, nervous system, immunity, and cancers (<xref ref-type="bibr" rid="bib3">Baillie et al., 2019</xref>). For example, PDE3 inhibitors are used to treat heart failure and peripheral artery disease, and PDE4 inhibitors are approved to treat inflammatory diseases (<xref ref-type="bibr" rid="bib15">Hsien Lai et al., 2020</xref>). Multiple studies have shown that PDEs, such as PDE4 and PDE5, play a vital role in the progression of tumors and are regarded as potential therapeutic targets for cancer treatment (<xref ref-type="bibr" rid="bib15">Hsien Lai et al., 2020</xref>; <xref ref-type="bibr" rid="bib17">Huang et al., 2020</xref>). The PDE1 family member has three subtypes, PDE1A, PDE1B, and PDE1C, with different affinities for cAMP and cGMP (<xref ref-type="bibr" rid="bib28">Samidurai et al., 2021</xref>). The effect and mechanism of PDE1 in regulating cancer progression remain elusive.</p><p><italic>N</italic><sup>6</sup>-methyladenosine (m<sup>6</sup>A) is the most abundant RNA modification, and the process of m<sup>6</sup>A modification is reversible: m<sup>6</sup>A is installed by ‘writers’, removed by ‘erasers’, and recognized by ‘readers’ (<xref ref-type="bibr" rid="bib20">Liu et al., 2023</xref>). YT521-B homology domain family member 2 (YTHDF2), belonging to the YTH domain protein family, has been validated as m<sup>6</sup>A ‘reader’ and regulates the stability of messenger RNAs (mRNAs) (<xref ref-type="bibr" rid="bib8">Chen et al., 2022</xref>). YTHDF2 promotes the progression of lung adenocarcinoma by recognizing m<sup>6</sup>A modification and influencing mRNA fate (<xref ref-type="bibr" rid="bib19">Li et al., 2021</xref>). Furthermore, YTHDF2 orchestrates the reprogramming of tumor-associated macrophages in the tumor microenvironment (TME), and YTHDF2 is an effective target to enhance cancer immunotherapy (<xref ref-type="bibr" rid="bib21">Ma et al., 2023</xref>). Functional analysis identifies that PDE1A is a promoter of NSCLC metastasis through its interaction with YTHDF2.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>PDE1A overexpression predicts a poor prognosis in lung cancer patients</title><p>First, immunohistochemistry analysis revealed that PDE1A expression was significantly higher in lung cancer tissues compared to normal lung tissues (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib32">Uhlén et al., 2015</xref>; <xref ref-type="bibr" rid="bib33">Uhlen et al., 2017</xref>). As shown in <xref ref-type="fig" rid="fig1">Figure 1B</xref>, overexpression of PDE1A was also observed in three NSCLC cell lines compared with normal human lung fibroblasts (HELF cells). Additionally, the overexpression of PDE1A was also observed in lung cancer from high-risk patients compared with low-risk patients (p&lt;0.0001, <xref ref-type="fig" rid="fig1">Figure 1C</xref>). Lung cancer patients in the high-risk group had shorter survival times than those in the low-risk group (<xref ref-type="fig" rid="fig1">Figure 1D</xref>; <xref ref-type="bibr" rid="bib1">Aguirre-Gamboa et al., 2013</xref>; <xref ref-type="bibr" rid="bib9">Chitale et al., 2009</xref>). Furthermore, lung cancer patients with high levels of PDE1A in their tumors had shorter overall survival than those with low PDE1A expression, indicating that PDE1A overexpression was correlated with a poor prognosis in lung cancer patients (<xref ref-type="fig" rid="fig1">Figure 1E</xref>; <xref ref-type="bibr" rid="bib27">Rousseaux et al., 2013</xref>; <xref ref-type="bibr" rid="bib13">Goswami and Nakshatri, 2014</xref>). Thus, PDE1A might be a novel prognostic predictor in lung cancer treatment and contribute to lung cancer progression.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>High expression of phosphodiesterase 1A (PDE1A) predicts a poor prognosis of lung cancer patients.</title><p>(<bold>A</bold>) The expression of PDE1A was detected in non-small cell lung cancer (NSCLC) and normal lung tissue. It was obtained from The Human Protein Atlas (<ext-link ext-link-type="uri" xlink:href="https://www.proteinatlas.org/">https://www.proteinatlas.org/</ext-link>). IOD/area means integral optical density/area. t-Test was used to compare the difference between lung cancer and normal lung groups, <sup>**</sup><italic>P</italic> &lt; 0.01. (<bold>B</bold>) The expression of PDE1A in human lung fibroblasts (HELF), A549, NCI-H1299, and NCI-H460 cells was detected by western blot. (<bold>C and D</bold>) Box plot analysis of the PDE1A messenger RNA (mRNA) levels in clinical lung cancer tissue samples. It was collected, and statistical analyses were performed from SurvExpress (<ext-link ext-link-type="uri" xlink:href="http://bioinformatica.mty.itesm.mx:8080/Biomatec/SurvivaX.jsp">http://bioinformatica.mty.itesm.mx:8080/Biomatec/SurvivaX.jsp</ext-link>). Gene: PDE1A; Access database numbers: Chitale lung (n=185); Censored: recurrence months or survival months. (<bold>E</bold>) It was collected from PROGgene V2 Prognostic Database (<ext-link ext-link-type="uri" xlink:href="http://www.progtools.net/gene/index.php">http://www.progtools.net/gene/index.php</ext-link>). Survival analysis is done using backend R script which employs R library ‘survival’ to perform Cox proportional hazards analysis (function ‘coxph’) and to plot prognostic plots (function ‘survfit’). Single-user input genes: PDE1A; Cancer type: LUNG; Survival measure: death; Bifurcate gene expression at: median; GSE30219-Off-context gene expression in lung cancer identifies a group of metastatic-prone tumors.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Raw images for western blot shown in <xref ref-type="fig" rid="fig1">Figure 1B</xref> (labelled).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98903-fig1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Raw images for western blot shown in <xref ref-type="fig" rid="fig1">Figure 1B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98903-fig1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98903-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>The expression of phosphodiesterase 1A (PDE1A) in normal lung (<bold>A</bold>) and lung cancer (<bold>B</bold>).</title><p>It was obtained from The Human Protein Atlas (<ext-link ext-link-type="uri" xlink:href="https://www.proteinatlas.org/">https://www.proteinatlas.org/</ext-link>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98903-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>The biological processes related to phosphodiesterase 1A (PDE1A) in non-small cell lung cancer (NSCLC) are predicted using LinkedOmics.</title><p>Data collected from LinkedOmics (<ext-link ext-link-type="uri" xlink:href="https://www.linkedomics.org/admin.php">https://www.linkedomics.org/admin.php</ext-link>) are shown. Overrepresentation enrichment analysis (ORA) (<bold>A</bold>) and gene set enrichment analysis (GSEA) (<bold>B</bold>) were performed to analyze the biological processes related to PDE1A in NSCLC. Sample cohort: TCGA_NSCLC; Institute: UNC; Data type: RNAseq; Platform: HiSeq RNA; Attribute: PDE1A; Statistical methods: Spearman’s correlation test; Patients: 515; Tools: ORA and GSEA; Gene Ontology analysis: biological process. (<bold>C</bold>) GSEA demonstrated that PDE1A participated in mesenchyme development and the cellular response to VEGF stimulus.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98903-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>The expression of phosphodiesterase 1A (PDE1A) does not affect the proliferation of non-small cell lung cancer (NSCLC) cells.</title><p>(<bold>A–B</bold>) NSCLC cells were transfected with PDE1A siRNA or control siRNA (<bold>A</bold>) and empty vector or PDE1A plasmid (<bold>B</bold>) for 24 hr in six-well plates, then transferred to 96-well plates for the indicated times, and finally subjected to sulforhodamine B (SRB) assay (n=3).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98903-fig1-figsupp3-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>PDE1A promotes the metastasis and EMT of NSCLC cells both in vitro and in vivo</title><p>To investigate the biological function of PDE1A in lung cancer development, gene set enrichment analysis (GSEA) and overrepresentation enrichment analysis (ORA) were performed to analyze the biological process of PDE1A in NSCLC using LinkedOmics (<xref ref-type="bibr" rid="bib34">Vasaikar et al., 2018</xref>). As shown in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>, PDE1A might be involved in the adhesion, migration, and motility of NSCLC cells, which are critical parameters in the metastatic dissemination of cancer cells. Tumor angiogenesis, the recruitment of new blood vessels, enables a pre-existing tumor to grow and metastasize (<xref ref-type="bibr" rid="bib25">Onn and Herbst, 2003</xref>). PDE1A might also participate in mesenchyme development, angiogenesis, vasculature development, cellular response to VEGF stimulus, blood vessel morphogenesis, and development (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). Thus, PDE1A is proposed to enhance the metastatic potential of NSCLC cells.</p><p>First, PDE1A silencing did not cause a significant decrease in the proliferation of NSCLC cells relative to that in the control siRNA group (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref>). Moreover, PDE1A overexpression had no significant effect on the proliferation of NSCLC cells (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3B</xref>). As bioinformatics analysis demonstrated that PDE1A might promote the metastatic potential of NSCLC cells, wound healing and Transwell assays were used to investigate the migration and invasion capacity of PDE1 family members. Knockdown of PDE1 family members suppressed the migratory ability of NCI-H1299 cells, and siPDE1A exerted a stronger suppression effect on the migration of NCI-H1299 cells than siPDE1B and siPDE1C transfection (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Meanwhile, siPDE1A resulted in more profound suppression of epithelial-mesenchymal transition (EMT) progression in NCI-H1299 cells than siPDE1B and siPDE1C transfection (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). Thus, PDE1 family members, particularly PDE1A, might be involved in the metastatic behavior of NSCLC cells.</p><p>As shown in <xref ref-type="fig" rid="fig2">Figure 2A and B</xref>, suppression of PDE1A markedly reduced the migratory and invasive capacity of NSCLC cell lines. The wound healing assay also showed that NSCLC cells with PDE1A knockdown had a slower wound closure rate than control siRNA-transfected cells (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref>). Furthermore, PDE1A knockdown increased E-cadherin expression and reduced N-cadherin expression, indicating that PDE1A silencing suppressed EMT progression in NSCLC cells (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Meanwhile, the PDE1 inhibitor vinpocetine significantly suppressed the migration and EMT of NSCLC cells (<xref ref-type="fig" rid="fig2">Figure 2F–H</xref>). To determine the effects of PDE1A on NSCLC cell migration and invasion in vivo, nude mouse models were established using PDE1A-shRNA- and control-shRNA-treated NCI-H1299 cells. As shown in <xref ref-type="fig" rid="fig2">Figure 2I</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C and D</xref>, the number of pulmonary metastatic nodules was decreased in the PDE1A-shRNA group compared with the control-shRNA group in nude mice.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Phosphodiesterase 1A (PDE1A) knockdown suppresses the metastasis of non-small cell lung cancer (NSCLC) cells.</title><p>(<bold>A–B</bold>) NSCLC cells were transfected with control siRNA and PDE1A siRNA for 24 hr. Cells were transferred to Transwell chambers without or with a Matrigel coating on the insert membrane, and the cell migrative and invasive abilities were determined, respectively (n=3). (<bold>C–D</bold>) NSCLC cells were transfected with control siRNA and PDE1A siRNA for 24 hr, and the wound healing assay was established in NSCLC cells (n=3). (<bold>E</bold>) NSCLC cells were transfected with control siRNA and PDE1A siRNA for 48 hr, and the expression of indicated proteins was detected. (<bold>F–G</bold>) NSCLC cells were treated with DMSO or vinpocetine (5, 10, 20 µM) for 24 hr, and the migrative ability of treated NSCLC cells was determined using the Transwell assay for 24 hr (n=3). (<bold>H</bold>) NSCLC cells were treated with DMSO or vinpocetine (5, 10, 20 µM) for 24 hr, and the expression of indicated proteins was determined. (<bold>I</bold>) The pulmonary metastatic nodules were stained using H&amp;E staining and counted in nude mice harboring NCI-H1299 cells transfected with PDE1A shRNA and control shRNA (n=6). <sup>**</sup><italic>P</italic> &lt; 0.01, <sup>***</sup><italic>P</italic> &lt; 0.001.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Raw images for western blots shown in <xref ref-type="fig" rid="fig2">Figure 2</xref> (labelled).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98903-fig2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Raw images for western blots shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98903-fig2-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98903-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Phosphodiesterase 1A (PDE1A) silence suppresses the metastasis of non-small cell lung cancer (NSCLC) cells.</title><p>(<bold>A</bold>) NSCLC cells were transfected with control siRNA, siPDE1A, siPDE1B, and siPDE1C for 24 hr, and cells were transferred to Transwell chambers without a Matrigel coating on the insert membrane, and the cell migration was determined after 24 hr, (n=3). (<bold>B</bold>) NSCLC cells were transfected with indicated siRNA for 48 hr, and the expression of the indicated proteins was detected. (<bold>C</bold>) The lungs of nude mice were separated and stained with Bouin’s solution, and the pulmonary metastatic nodules were counted. (<bold>D</bold>) The relative body weight of each group in the in vivo metastasis studies in <xref ref-type="fig" rid="fig2">Figure 2I</xref>, (n=6). (E) The lungs in nude mice were stained using H&amp;E. <sup>***</sup><italic>P</italic> &lt; 0.001.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Raw images for western blot shown in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref> (labelled).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98903-fig2-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata2"><label>Figure 2—figure supplement 1—source data 2.</label><caption><title>Raw images for western blot shown in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98903-fig2-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98903-fig2-figsupp1-v1.tif"/></fig></fig-group><p>In contrast, PDE1A overexpression significantly enhanced the migratory and invasive capacities of NSCLC cells (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>). In addition, NSCLC cells with high PDE1A expression had a higher wound closure rate than those transfected with empty vector (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Meanwhile, PDE1A overexpression decreased E-cadherin expression and elevated N-cadherin expression, indicating that PDE1A promoted EMT progression of NSCLC cells (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). NSCLC cell lines with varying invasive potential were generated via repeated Transwell selection to compare PDE1A expression between highly and poorly invasive cells (<xref ref-type="fig" rid="fig3">Figure 3E</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A and B</xref>). The protein and mRNA levels of PDE1A were higher in highly invasive NSCLC cells than in NSCLC cells with low invasive potential (<xref ref-type="fig" rid="fig3">Figure 3F and G</xref>). In an in vivo nude mouse experiment, NSCLC cells overexpressing PDE1A produced more pulmonary metastatic nodules than the parental NSCLC cells (<xref ref-type="fig" rid="fig3">Figure 3H</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C and D</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Phosphodiesterase 1A (PDE1A) promotes the metastasis and epithelial-mesenchymal transition (EMT) of non-small cell lung cancer (NSCLC) cells.</title><p>(<bold>A–B</bold>) NSCLC cells were transfected with PDE1A plasmid and empty vector for 24 hr. Cells were transferred to Transwell chambers without (<bold>A</bold>) or with (<bold>B</bold>) a Matrigel coating on the insert membrane, and the cell migrative and invasive abilities were determined, respectively, (n=3). (<bold>C</bold>) NSCLC cells were transfected with PDE1A plasmid and empty vector for 24 hr, and the wound healing assay was established in NSCLC cells, (n=3). (<bold>D</bold>) NSCLC cells were transfected with PDE1A plasmid and empty vector for 48 hr, and the expression of indicated proteins was detected. (<bold>E</bold>) The highly invasive NSCLC cells were separated using the Transwell chamber assay, and P3 cells were obtained from P0 cells after three generations. (<bold>F–G</bold>) The messenger RNA (mRNA) (<bold>F</bold>) and protein (<bold>G</bold>) levels of indicated genes were determined in P3 and P0 NSCLC cells. (<bold>H</bold>) The pulmonary metastatic nodules were stained using H&amp;E and Bouin’s solution and counted in nude mice harboring NCI-H1299 cells transfected with PDE1A plasmid and empty vector, (n=6). <sup>**</sup><italic>P</italic> &lt; 0.01, <sup>***</sup><italic>P</italic> &lt; 0.001.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Raw images for western blots shown in <xref ref-type="fig" rid="fig3">Figure 3</xref> (labelled).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98903-fig3-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Raw images for western blots shown in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98903-fig3-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98903-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Phosphodiesterase 1A (PDE1A) promotes the metastasis of non-small cell lung cancer (NSCLC) cells.</title><p>(<bold>A</bold>) The migrative abilities of P3 and P0 NSCLC cells were determined, (n=3). (<bold>B</bold>) The messenger RNA (mRNA) levels of indicated genes were determined in P3 and P0 NSCLC cells using quantitative real‑time PCR (qRT-PCR), (n=3). (<bold>C</bold>) Before the NSCLC cells were injected into the nude mice, the migrative abilities of NSCLC cells were determined using Transwell assay. (<bold>D</bold>) The relative body weight of each group in the in vivo metastasis studies in <xref ref-type="fig" rid="fig3">Figure 3H</xref>, (n=6). (E) The lungs in nude mice were stained using H&amp;E. <sup>**</sup><italic>P</italic> &lt; 0.01, <sup>***</sup><italic>P</italic> &lt; 0.001.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Raw images for western blots shown in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref> (labelled).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98903-fig3-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata2"><label>Figure 3—figure supplement 1—source data 2.</label><caption><title>Raw images for western blots shown in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98903-fig3-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98903-fig3-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>NSCLC cells overexpressing PDE1A promote angiogenesis in the TME</title><p>GSEA demonstrated that PDE1A expression was positively correlated with angiogenesis in lung cancer (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). To mimic the TME, a coculture system of NSCLC cells and vascular endothelial cells was established (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). NSCLC cells overexpressing PDE1A promoted the migration of human umbilical vein endothelial cells (HUVECs), and NSCLC cells with low levels of PDE1A suppressed the migration of HUVECs (<xref ref-type="fig" rid="fig4">Figure 4C and D</xref>). Next, NSCLC cells were treated with GW4869 to reduce exosome release, and GW4869 suppressed the enhancement of the migratory ability of HUVECs induced by NSCLC cells overexpressing PDE1A (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Meanwhile, compared with negative control, shPDE1A significantly suppressed tumor angiogenesis of NSCLC in vivo (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). Thus, NSCLC cells overexpressing PDE1A promote angiogenesis in the TME.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Non-small cell lung cancer (NSCLC) cells overexpressing phosphodiesterase 1A (PDE1A) promote angiogenesis in the tumor microenvironment (TME).</title><p>(<bold>A</bold>) It was collected from LinkedOmics. Statistical tests in LinkFinder include Pearson’s correlation coefficient, Spearman’s rank correlation, Student’s t-test, Wilcoxon test, analysis of variance, Kruskal-Wallis analysis, Fisher’s exact test, Chi-squared test, Jonckheere’s trend test, and Cox’s regression analysis. Multiple-test correction is performed using the Benjamini and Hochberg method to generate the false discovery rate. (<bold>B–D</bold>) NSCLC cells were transfected with empty vector/PDE1A overexpressing plasmid or control siRNA/siPDE1A for 48 hr, and then NSCLC cells were placed on the upper panel of Transwell with 0.4 μm insert, human umbilical vein endothelial cells (HUVECs) were placed on the lower panel of Transwell, and wound healing assay was performed to determine the migrative abilities of HUVECs, (n=3). (<bold>E</bold>) NSCLC cells with PDE1A overexpression were treated with 10 µM GW4869, and a wound healing assay was performed to determine the migrative abilities of HUVECs, (n=3). (<bold>F</bold>) NSCLC cells were transfected with empty vector or shPDE1A, then cells were transplanted into nude mice via subcutaneous injection, and the blood vessels were counted after 60 days, (n=6). <sup>**</sup><italic>P</italic> &lt; 0.01, <sup>***</sup><italic>P</italic> &lt; 0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98903-fig4-v1.tif"/></fig></sec><sec id="s2-4"><title>PDE1A promotes the metastasis of NSCLC cells via the STAT3 signaling pathway</title><p>Then, the dependence of PDE1A-enhanced metastasis on cAMP metabolic activity was investigated. As shown in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>, the cAMP inhibitor SQ22536 failed to rescue the migrative ability suppressed by siPDE1A in NSCLC cells, indicating that the basic molecular function might not be involved in the metastasis of PDE1A. To better explore the mechanism of PDE1A in NSCLC progression, bioinformatic analysis of PDE1A coexpressed genes was performed, which revealed that PDE1A might be involved in the JAK/STAT3, Hedgehog, and TGF-β pathways in NSCLC (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Meanwhile, GSEA enrichment analysis demonstrated that PDE1A might participate in IL-6 production (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Thus, IL-6/JAK/STAT3 signaling is involved in PDE1A-mediated promotion of metastasis in NSCLC. As shown in <xref ref-type="fig" rid="fig5">Figure 5C</xref>, PDE1A overexpression increased the phosphorylation level of STAT3 in NSCLC cells. In contrast, PDE1A knockdown or the PDE1 inhibitor vinpocetine suppressed the phosphorylation of STAT3 in NSCLC cells (<xref ref-type="fig" rid="fig5">Figure 5D and E</xref>). Moreover, STAT3 suppression by siRNA or SH-4–54 significantly reversed the enhancement of NSCLC cell migration induced by PDE1A overexpression (<xref ref-type="fig" rid="fig5">Figure 5F and G</xref>). In addition, the suppression of STAT3 inhibited PDE1A-induced EMT progression in NSCLC cells (<xref ref-type="fig" rid="fig5">Figure 5H and I</xref>). Thus, PDE1A promoted the metastasis of NSCLC cells via activating the STAT3 signaling pathway, but the direct interaction between PDE1A and STAT3 could not be observed in NSCLC cells (<xref ref-type="fig" rid="fig5">Figure 5J</xref>). Moreover, PDE1A was mainly overexpressed in the cytoplasm in NSCLC cells (<xref ref-type="fig" rid="fig5">Figure 5K</xref>). Subsequently, the mechanism by which PDE1A promotes the STAT3 signaling pathway in the cytoplasm was further explored.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Phosphodiesterase 1A (PDE1A) promotes the metastasis of non-small cell lung cancer (NSCLC) cells via the STAT3 signaling pathway.</title><p>(<bold>A</bold>) A Venn diagram was generated using LinkedOmics, and overrepresentation enrichment analysis (ORA) was performed to analyze the molecular pathway regulated by PDE1A in NSCLC. Sample cohort: TCGA_NSCLC; Institute: UNC; Data type: RNAseq; Platform: HiSeq RNA; Attribute: PDE1A; Statistical methods: Spearman’s correlation test; Patients: 515; Tools: ORA; Gene Ontology analysis: WikiPathways and PANTHER Pathway; Select rank criteria: FDR; Select sign: Positively correlated; Significance level: 0.05; TOP40 was selected to generate the Venn diagram. (<bold>B</bold>) Gene set enrichment analysis (GSEA) was performed to analyze the biological process of PDE1A in NSCLC. (<bold>C</bold>) NSCLC cells were transfected with PDE1A plasmid and empty vector for 48 hr, and the expression of indicated proteins was detected. (<bold>D</bold>) NSCLC cells were transfected with control siRNA and PDE1A siRNA for 48 hr, and the expression of indicated proteins was detected. (<bold>E</bold>) NSCLC cells were treated with DMSO or vinpocetine (5, 10, 20 µM) for 24 hr, and the expression of indicated proteins was determined. (<bold>F</bold>) NSCLC cells overexpressing PDE1A were transfected with control siRNA and STAT3 siRNA for 48 hr, and the migrative abilities of NSCLC cells were determined by Transwell assay, (n=3). (<bold>G</bold>) NSCLC cells overexpressing PDE1A were treated with STAT3 inhibitor SH-4–54 (5 µM) for 24 hr. The migrative abilities of NSCLC cells were determined by Transwell assay, (n=3). (<bold>H</bold>) NSCLC cells overexpressing PDE1A were transfected with control siRNA and STAT3 siRNA for 48 hr, and the expression of indicated protein was detected by western blot. (<bold>I</bold>) NSCLC cells overexpressing PDE1A were treated with STAT3 inhibitor SH-4–54 (5 µM) for 24 hr, and the expression of indicated protein was detected by western blot. (<bold>J</bold>) The interaction between PDE1A and STAT3 was determined by immunoprecipitation. (<bold>K</bold>) NCI-H1299 cells were transfected with empty vector and PDE1A overexpressing plasmid for 48 hr, and the contribution of PDE1A in the cytoplasm and nucleus was determined.<sup>**</sup><italic>P</italic> &lt; 0.01, <sup>***</sup><italic>P</italic> &lt; 0.001.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Raw images for western blots shown in <xref ref-type="fig" rid="fig5">Figure 5</xref> (labelled).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98903-fig5-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Raw images for western blots shown in <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98903-fig5-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98903-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Phosphodiesterase 1A (PDE1A) promotes the metastatic potential in a cyclic adenosine monophosphate (cAMP)-independent manner.</title><p>Non-small cell lung cancer (NSCLC) cells were transfected with control siRNA and PDE1A siRNA. After 24 hr, cells were collected for Transwell assay. Cells were treated with DMSO or 5 µM SQ22536 for 24 hr, and the migrative abilities of NSCLC cells were determined, (n=3). ns, not significant, <sup>**</sup><italic>P</italic> &lt; 0.01.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Raw images for western blots related to <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref> (labelled).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98903-fig5-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata2"><label>Figure 5—figure supplement 1—source data 2.</label><caption><title>Raw images for western blots related to <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98903-fig5-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98903-fig5-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-5"><title>PDE1A physically interacts with YTHDF2 and promotes the metastasis of NSCLC cells</title><p>To investigate the mechanism by which PDE1A promotes NSCLC metastasis and activates the STAT3 pathway, the proteins interacting with PDE1A in NSCLC were determined using immunoprecipitation followed by mass spectrometry analysis (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). To identify key proteins involved in PDE1A-mediated STAT3 activation, a Venn analysis revealed nine overlapping genes among STAT3-coexpressed genes in NSCLC samples, PDE1A-interacting proteins, and genes overexpressed in NSCLC compared to normal tissues (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Meanwhile, GO enrichment analysis of PDE1A-interacting genes was used to predict the molecular function of PDE1A, and PDE1A might participate in m<sup>6</sup>A-containing RNA binding in NSCLC progression (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Based on this, it was hypothesized that PDE1A may interact with YTHDF2 and be involved in the binding of m<sup>6</sup>A-modified RNA during NSCLC progression. The physical binding between PDE1A and YTHDF2 was confirmed by silver staining and immunoprecipitation (<xref ref-type="fig" rid="fig6">Figure 6C and D</xref>). Furthermore, YTHDF2 knockdown reversed the enhancement of NSCLC migration induced by PDE1A overexpression, indicating that PDE1A might interact with YTHDF2 and promote the metastasis of NSCLC (<xref ref-type="fig" rid="fig6">Figure 6E</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A and B</xref>). The mRNA and protein levels of YTHDF2 were upregulated in NSCLC compared with normal lung tissues (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C and D</xref>; <xref ref-type="bibr" rid="bib6">Chandrashekar et al., 2017</xref>). In addition, YTHDF2 overexpression predicted poor outcomes in lung cancer patients (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1E</xref>; <xref ref-type="bibr" rid="bib27">Rousseaux et al., 2013</xref>; <xref ref-type="bibr" rid="bib13">Goswami and Nakshatri, 2014</xref>). Meanwhile, the activation of STAT3 by PDE1A could be reversed by YTHDF2 knockdown in NSCLC cells (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). Furthermore, PDE1A was positively correlated with YTHDF2 expression with a Pearson’s correlation coefficient above 0.3 in NSCLC tissues (<xref ref-type="fig" rid="fig6">Figure 6G</xref>; <xref ref-type="bibr" rid="bib6">Chandrashekar et al., 2017</xref>). Thus, PDE1A might regulate the STAT3 signaling pathway via interacting with YTHDF2.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>PDE1A physically interacts with YT521-B homology domain family member 2 (YTHDF2) and promotes the metastasis of non-small cell lung cancer (NSCLC) cells.</title><p>(<bold>A</bold>) Venn diagram showing the overlap among PDE1A-interacting proteins (it was collected from mass spectrometry analysis in NSCLC cells), STAT3-coexpressed genes (collected from gene correlation using UALCAN), upregulated proteins in NSCLC compared with normal tissues (analyzed by UALCAN based on CPTAC database), and upregulated genes in NSCLC compared with normal tissues (analyzed by UALCAN based on TCGA database). Pearson’s correlation analysis of UALCAN was used to evaluate gene correlation analyses, and Welch’s t-test was estimated to detect the significance of differences in expression levels between two groups. (<bold>B</bold>) GO enrichment analysis of PDE1A-interacting genes. (<bold>C</bold>) Immunoprecipitation followed by silver staining was performed to identify protein and protein interaction using A549 cell lysate with the anti-PDE1A antibody. (<bold>D</bold>) Immunoprecipitation was used to confirm protein and protein interaction in NCI-H1299 cells. (<bold>E</bold>) NSCLC cells overexpressing PDE1A were transfected with control siRNA and YTHDF2 siRNA for 48 hr, and the migrative abilities of NSCLC cells were determined by Transwell assay, (n=3). (<bold>F</bold>) NSCLC cells overexpressing PDE1A were transfected with control siRNA and YTHDF2 siRNA for 48 hr, and the expression of indicated protein was detected by western blot. <sup>***</sup><italic>P</italic> &lt; 0.001.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Raw images for western blots shown in <xref ref-type="fig" rid="fig6">Figure 6</xref> (labelled).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98903-fig6-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Raw images for western blots shown in <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98903-fig6-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98903-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>YT521-B homology domain family member 2 (YTHDF2) predicts poor outcomes for lung cancer patients.</title><p>(<bold>A–B</bold>) Non-small cell lung cancer (NSCLC) cells were transfected with control siRNA and YTHDF2 siRNA for 48 hr, and the knockdown efficiency of YTHDF2 was confirmed by western blot (<bold>A</bold>) and quantitative real‑time PCR (qRT-PCR) (<bold>B</bold>), (n=3). (<bold>C–D</bold>) The messenger RNA (mRNA) and protein levels of phosphodiesterase 1A (PDE1A) in NSCLC and normal lung tissues are shown. It was collected from UALCAN and shown. Gene: YTHDF2; TCGA dataset: Lung adenocarcinoma (<bold>C</bold>); CPTAC dataset: Lung adenocarcinoma (<bold>D</bold>). (<bold>E</bold>) The prognostic value of YTHDF2 in NSCLC patients was identified using the PROGgeneV2 online tool (<ext-link ext-link-type="uri" xlink:href="https://www.progtools.net/gene">https://www.progtools.net/gene</ext-link>). <sup>***</sup><italic>P</italic> &lt; 0.001.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Raw images for western blots shown in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref> (labelled).</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-98903-fig6-figsupp1-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig6s1sdata2"><label>Figure 6—figure supplement 1—source data 2.</label><caption><title>Raw images for western blots shown in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-98903-fig6-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98903-fig6-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-6"><title>PDE1A interacts with YTHDF2 to regulate the SOCS2/STAT3 signaling pathway</title><p>To investigate how the PDE1A/YTHDF2 complex regulates STAT3 signaling, Venn analysis identified 33 genes overlapping among YTHDF2-bound RNAs and genes coexpressed with YTHDF2 and STAT3 in lung cancer (<xref ref-type="bibr" rid="bib30">Shi et al., 2017</xref>; <xref ref-type="bibr" rid="bib4">Bartha and Győrffy, 2021</xref>; <xref ref-type="bibr" rid="bib5">Cerami et al., 2012</xref>; <xref ref-type="bibr" rid="bib12">Gao et al., 2013</xref>; <xref ref-type="fig" rid="fig7">Figure 7A</xref> and <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). Then, the interactions between the YTHDF2 protein and the mRNAs of 33 overlapping genes were predicted by the RNA-Protein Interaction Prediction online tool. There were three predicted targets of YTHDF2 with high scores and highly correlated with STAT3 signaling as previously reported, including NRF2, SOCS2, and MET (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>; <xref ref-type="bibr" rid="bib24">Muppirala et al., 2011</xref>). SOCS family members are cytokine-inducible negative regulators of the JAK/STAT pathway, and SOCS2 suppresses the binding of JAK2 and STAT3, the activity of JAK, and STAT3 activation (<xref ref-type="bibr" rid="bib29">Sen et al., 2012</xref>). It was hypothesized that PDE1A might interact with YTHDF2, affect the stability of <italic>SOCS2</italic> mRNA, and thereby regulate the STAT3 signaling pathway in NSCLC cells. As shown in <xref ref-type="fig" rid="fig7">Figure 7B</xref>, the interaction between YTHDF2 protein and SOCS2 mRNA was confirmed by RIP, and the binding between PDE1A protein and SOCS2 mRNA was also demonstrated using RIP. Meanwhile, siPDE1A significantly enhanced the stability of SOCS2 mRNA in NSCLC cells (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). Furthermore, YTHDF2 or PDE1A negatively regulated the expression of SOCS2 mRNA in NSCLC cells, and YTHDF2 overexpression successfully reversed the siPDE1A-induced SOCS2 mRNA accumulation. In contrast, siYTHDF2 enhanced siPDE1A-induced SOCS2 mRNA accumulation (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). Thus, YTHDF2 might negatively regulate the expression of SOCS2 mRNA via cooperating with PDE1A.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Phosphodiesterase 1A (PDE1A) interacts with YT521-B homology domain family member 2 (YTHDF2) to regulate SOCS2/STAT3 signaling pathway.</title><p>(<bold>A</bold>) YTHDF2-RNA complexes were identified by LC-MS/MS and collected from reference; YTHDF2 correlated genes were collected from TNMplot (<ext-link ext-link-type="uri" xlink:href="https://tnmplot.com/analysis/">https://tnmplot.com/analysis/</ext-link>), Gene: YTHDF2, Gene vs. all genes correlation: Genechip data, Tissue: Lung; STAT3 correlated genes were collected from cBioPortal (<ext-link ext-link-type="uri" xlink:href="http://www.cbioportal.org/">http://www.cbioportal.org/</ext-link>), Lung cancer (SMC, cancer research 2016); n=22; Gene: STAT3. The interaction between YTHDF2 protein and the messenger RNA (mRNA) of 33 overlapping genes was predicted by RNA-Protein Interaction Prediction (<ext-link ext-link-type="uri" xlink:href="http://pridb.gdcb.iastate.edu/RPISeq/index.html">http://pridb.gdcb.iastate.edu/RPISeq/index.html</ext-link>), and the values of RF classifier and SVM classifier above 0.5 were considered positive. Comparison of the normal and the tumorous samples was performed by the Mann-Whitney U test, and normal, tumorous, and metastatic tissue gene comparison can be analyzed using the Kruskal-Wallis test. (<bold>B</bold>) The interactions between protein and mRNAs were verified by RNA binding protein immunoprecipitation (RIP) experiments. (<bold>C</bold>) Non-small cell lung cancer (NSCLC) cells were transfected with control siRNA and siPDE1A for 48 hr, and the stability of mRNA was determined by quantitative real‑time PCR (qRT-PCR), (n=3). (<bold>D</bold>) NSCLC cells were transfected with control siRNA and siPDE1A for 48 hr, and the expression of SOCS2 mRNA was determined by qRT-PCR, (n=3). <sup>**</sup><italic>P</italic> &lt; 0.01, <sup>***</sup><italic>P</italic> &lt; 0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98903-fig7-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>NSCLC is becoming a leading cause of death globally due to its fast progression and metastatic potential, and effective therapeutic targets are urgently needed to block NSCLC metastasis (<xref ref-type="bibr" rid="bib36">Zhu et al., 2020</xref>). PDEs are regarded as therapeutic targets for multiple diseases, but the feasibility of targeting PDEs to treat NSCLC metastasis may need further investigation (<xref ref-type="bibr" rid="bib7">Chen and Yan, 2021</xref>). It is the first evidence that PDE1 promotes metastasis and EMT progression in NSCLC cells. Furthermore, the expression of PDE1A was closely correlated with the disease progression of NSCLC. Thus, PDE1A might be an efficacious therapeutic target for patients with metastatic NSCLC.</p><p>The stimulation of the PDEs requires physiological concentrations of Ca<sup>2+</sup> and calmodulin, and Ca<sup>2+</sup>/calmodulin-dependent cyclic nucleotide PDE1 is involved in the communication between the cyclic nucleotide and Ca<sup>2+</sup> second messenger systems (<xref ref-type="bibr" rid="bib18">Kakkar et al., 1999</xref>). The increasing of Ca<sup>2+</sup> in cancer cells stimulates exosome biogenesis and release under both physiological and pathological conditions (<xref ref-type="bibr" rid="bib14">Han et al., 2022</xref>; <xref ref-type="bibr" rid="bib22">Messenger et al., 2018</xref>). It was hypothesized that PDE1A might be involved in exosome biogenesis and release in NSCLC cells, playing a crucial role in intercellular communication within the TME. GSEA showed that PDE1A might be involved in angiogenesis, vasculature development, and blood vessel development. Indeed, NSCLC cells overexpressing PDE1A promoted angiogenesis in the TME, and PDE1A knockdown significantly suppressed angiogenesis of NSCLC in vivo. Furthermore, an exosome release inhibitor successfully reversed the angiogenesis promoted by NSCLC cells overexpressing PDE1A. Thus, PDEs might play an important role in angiogenesis and the TME via regulating exosome biogenesis and release in cancer cells. Analysis of PDE1A co-expressed genes in NSCLC revealed a significant enrichment of the IL-6/JAK/STAT3 signaling pathway, suggesting its involvement as a downstream pathway of PDE1A. Furthermore, PDE1A promoted the metastasis of NSCLC cells via the STAT3 signaling pathway. Targeting the IL-6/JAK/STAT3 signaling pathway is considered a promising therapeutic strategy for the management of NSCLC (<xref ref-type="bibr" rid="bib23">Mohrherr et al., 2020</xref>). However, the direct interaction between PDE1A and STAT3 could not be observed in NSCLC cells. Subsequently, the mechanism by which PDE1A promotes the STAT3 signaling pathway was investigated. It demonstrated that PDE1A interacts with YTHDF2 and contributes to NSCLC progression, with the interaction between YTHDF2 and PDE1A being verified for the first time in NSCLC cells. Meanwhile, YTHDF2 might act as an m6A RNA ‘reader’ by interacting with PDE1A, but the mechanism might need further investigation. YTHDF2 destabilizes mRNAs via degrading target transcripts, but it also stabilizes important oncogenic drivers, such as <italic>MYC</italic> and <italic>VEGFA</italic> transcripts, in an m<sup>6</sup>A-dependent manner (<xref ref-type="bibr" rid="bib11">Dixit et al., 2021</xref>). It was demonstrated that YTHDF2 destabilized SOCS2 mRNA via interacting with PDE1A, but the mechanism by which YTHDF2 sorts mRNA might need further investigation. In addition, it is worth testing if PDE1A inhibition affects metastasis in lung cancer models and sensitizes cisplatin in resistant NSCLC cells in vitro and in vivo. The role of YTHDF2 in PDE1A-driven tumor metastasis should be elucidated in future studies.</p><p>Collectively, PDE1A promotes metastasis in NSCLC cells, and PDE1A overexpression is correlated with angiogenesis and poor outcomes of NSCLC patients. In addition, PDE1A interacts with YTHDF2 and regulates the JAK/STAT3 signaling pathway via degrading SOCS2 mRNA. Therefore, it reveals the effect and mechanism of PDE1A in promoting NSCLC metastasis. It not only uncovers a novel PDE1A/YTHDF2/STAT3 signaling pathway in NSCLC progression but also provides novel therapeutic strategies to treat NSCLC patients with metastasis.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Materials</title><p>Vinpocetine (V107535) was purchased from Aladdin (Shanghai, China). SH-4–54 (S7337), SQ22536 (S8283), and GW4869 (S7609) were obtained from Selleck Chemicals (Houston, TX, USA). Antibodies against β-actin (SC-1616) and GAPDH (SC-25778) were obtained from Santa Cruz Biotechnology (Dallas, TX, USA). Antibodies against N-cadherin (14215), STAT3 (9139), p-STAT3 (Y-705) (9145), Vimentin (5741), and JAK2 (3230S) were obtained from Cell Signaling Technology (Danvers, MA, USA). An antibody against α-tubulin (AT7819) was purchased from Beyotime Biotechnology (Shanghai, China). Antibodies against PDE1A (12442-2-AP), YTHDF2 (247441-AP), lamin B (12595-1-AP), and E-cadherin (20874-1-AP) were obtained from Proteintech (Rosemont, IL, USA).</p></sec><sec id="s4-2"><title>Cell lines and cell culture</title><p>Human NSCLC cell lines (A549, NCI-H1299, and NCI-H460), HELF, and HUVECs were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 100 U/ml penicillin/streptomycin. All the cell lines were purchased from the Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China), cultured at 37°C with 5% CO<sub>2</sub> and confirmed to be mycoplasma-free.</p></sec><sec id="s4-3"><title>siRNA transfection</title><p>Scramble siRNA, siPDE1A, siPDE1B, siPDE1C, siSTAT3, and siYTHDF2 were synthesized by GenePharma (Suzhou, China). Then, NSCLC cells were transfected with siRNA (40 nM) using PolyPlus-transfection reagent in accordance with the instructions. The sequences of siRNAs are summarized in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-4"><title>SRB assay</title><p>NSCLC cells were treated with the indicated compounds and subsequently fixed with ice-cold TCA and stained with 0.4% SRB (wt/vol) solution. Cell proliferation was determined by SRB assay according to the previously reported methods (<xref ref-type="bibr" rid="bib16">Hu et al., 2020</xref>).</p></sec><sec id="s4-5"><title>Wound healing assay</title><p>NSCLC cells were seeded on a 24-well plate and cultured as a monolayer to 90% confluence. The monolayer was scratched with a 10 µl pipette tip, and then the cells were cultured with FBS-free culture medium for 24 hr. Images of the wounded cell monolayer were taken using a microscope (Olympus, Japan) at 0 and 24 hr. The wound closure rate was calculated as follows: (G<sub>0</sub> – G<sub>24</sub>)/G<sub>0</sub> × 100%, where G<sub>0</sub> and G<sub>24</sub> represent the gap areas at 0 and 24 hr, respectively.</p></sec><sec id="s4-6"><title>Migration and invasion assays using Transwell</title><p>Migration and invasion assays were performed using a 24-well Transwell chamber system (pore size: 8 µm, Corning, USA). A total of 5×10<sup>4</sup> cells were seeded in the upper chamber of an insert with 0.4 ml serum-free culture media in 24-well plates. Then, 0.6 ml culture medium with 20% FBS was added to the lower chamber. For invasion assays, the upper transwell chamber of the insert was coated with Matrigel (BD Biosciences, Bedford, MA, USA) before plating cells. 50 μl of Matrigel was dissolved in 450 μl of culture medium and added 100 μl solution into the upper transwell chamber. After incubation for 24 hr, migratory or invasive cells were stained with 0.5% crystal violet and analyzed under a light microscope.</p></sec><sec id="s4-7"><title>Protein extraction and western blotting analysis</title><p>Briefly, cells were washed three times with cold PBS and pelleted. The pellet was resuspended in lysis buffer (NP40 lysate), incubated on ice with frequent vortexing for 30 min, and the lysate was obtained by centrifugation at 10,000×<italic>g</italic> for 30 min. Proteins were fractionated by SDS-PAGE, transferred onto PVDF membranes, blocked in 5% nonfat milk in PBS/Tween-20, and then blotted with specific primary antibody overnight at 4°C, followed by incubation with secondary antibody for 1 hr at room temperature. Bands were detected by the Odyssey CLX Image Studio system (version 5.0.21, LiCor Odyssey, LI-COR Biosciences).</p></sec><sec id="s4-8"><title>Immunoprecipitation and LC-MS/MS</title><p>For co-immunoprecipitation, the cells were lysed with IP buffer (20 mM HEPES, 25% glycerine, 210 mM NaCl, 1.5 mM MgCl<sub>2</sub>, 0.05 mM EDTA, 0.2% NP40, 1× cocktail, 1 mM PMSF, 2 mM DTT) and centrifuged at 10,000×<italic>g</italic> for 30 min at 4°C. The cell lysates were treated with protein G magnetic beads at 4°C for 1 hr. Subsequent immunoprecipitation reactions were set up with equal quantities of the lysates. Primary antibody was added to the lysate, and the mixture was incubated overnight with slow shaking at 4°C, and then incubated with protein G magnetic beads at 4°C for 1 hr. Subsequently, the lysates were centrifuged at 3000×<italic>g</italic> at 4°C for 5 min. The supernatant was aspirated, the protein G magnetic beads were washed three to four times with lysis buffer, and detection was performed using SDS-PAGE or LC-MS/MS (Micrometer Biotech Company, Hangzhou, China).</p></sec><sec id="s4-9"><title>Extraction of RNA and qRT-PCR</title><p>Total RNA was extracted from cells by utilizing TRIzol Reagent (Invitrogen, Thermo Fisher Scientific). RNA was reverse-transcribed into cDNA using an iScript cDNA Synthesis kit (Bio-Rad, Hercules, CA, USA). qRT-PCR was performed using the PerfectStart Green qPCR SuperMix kit (TransGen Biotech, Beijing, China). The levels of mRNA were analyzed by the Bio-Rad CFX96 real-time PCR system (Bio-Rad, Hercules, CA, USA). GAPDH was used as an endogenous control for mRNA qualification, and the 2<sup>-ΔΔCt</sup> method was applied to calculate the relative expression. The primers used are listed in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>.</p></sec><sec id="s4-10"><title>RNA binding protein immunoprecipitation</title><p>RNA binding protein immunoprecipitation assays were performed using a Magna RIP Kit (17-701, Millipore, MA, USA) following the manufacturer’s instructions. In brief, magnetic beads precoated with 5 μg normal antibodies against PDE1A/YTHDF2 or rabbit IgG (Millipore) were incubated with cell lysates at 4°C overnight. The beads containing immunoprecipitated RNA-protein complexes were treated with proteinase K to remove proteins. Then, RNAs of interest were purified with TRIzol and measured by qRT-PCR.</p></sec><sec id="s4-11"><title>Plasmid and shRNA transfection and infection</title><p>Two micrograms of overexpressing plasmid or shRNA of the indicated genes was transfected into cells using PolyPlus-transfection reagent. For shRNA used in lentivirus-mediated interference, complementary sense and antisense oligonucleotides encoding shRNAs targeting PDE1A were synthesized, annealed, and cloned into pLKO.TRC vector (Addgene, 10878). The PDE1A-FLAG overexpression plasmid was synthesized by GenScript (Nanjing, Jiangsu, China). YTHDF2-HA expression plasmids were synthesized via cloning YTHDF2 with an HA tag into the pcDNA3.1(-) vector.</p></sec><sec id="s4-12"><title>In vivo animal experiment</title><p>Female nude mice (BALB/c, 4–6 weeks of age) were obtained from Shanghai SLAC Laboratory Animal Co., Ltd. A total of 2 × 10<sup>6</sup> NCI-H1299 cells transfected with shPDE1A/control shRNA or PDE1A overexpressing plasmid/empty vector were suspended in 0.1 ml of PBS and injected into mice via the tail vein. After 60 days, the mice were sacrificed, and the lung tissues were collected to observe pulmonary nodules. The lung, liver, kidney, pancreas, and other tissues were separated, fixed in 4% paraformaldehyde, and stained using H&amp;E. All animal procedures were conducted in accordance with the guidelines and regulations approved by the Institutional Animal Care and Use Committee (IACUC) of Zhejiang University City College. Ethical approval for the study was obtained under protocol number 22001.</p></sec><sec id="s4-13"><title>mRNA stability assay</title><p>NSCLC cells were seeded in six-well plates and grown to approximately 30% confluence, followed by siRNA transfection and incubation for 24 hr. Then, cells were incubated with actinomycin D (5 μg/ml) for 0, 3, or 6 hr followed by RNA extraction. The half-life of mRNA was analyzed by qRT-PCR. The mRNA expression for each group at the indicated time was calculated and normalized to GAPDH.</p></sec><sec id="s4-14"><title>Statistical analysis</title><p>Data are presented as the mean ± SD from three independent experiments. Two-tailed Student’s t test was used to compare two groups. p-Values&lt;0.05 were considered significant. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con7"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con8"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con9"><p>Funding acquisition</p></fn><fn fn-type="con" id="con10"><p>Formal analysis</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Supervision, Funding acquisition</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>The experiments were performed in compliance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All procedures were approved by the Institutional Animal Care and Use Committee of Zhejiang University City College (No. 22001).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>The siRNA sequence used for knocking down the indicated genes.</title></caption><media xlink:href="elife-98903-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Primers sequences for detecting the expression of the indicated genes.</title></caption><media xlink:href="elife-98903-supp2-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Identification of PDE1A protein interactions by mass spectrometry.</title></caption><media xlink:href="elife-98903-supp3-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>The potential target genes of YTHDF2 in non-small cell lung cancer (NSCLC) cells.</title></caption><media xlink:href="elife-98903-supp4-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>The potential target genes of YTHDF2 in non-small cell lung cancer (NSCLC) cells.</title></caption><media xlink:href="elife-98903-supp5-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-98903-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><ack id="ack"><title>Acknowledgements</title><p>It was funded by Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China (LHDMY22H160001), Natural Science Foundation of Ningbo City (2022J206), National Natural Science Foundation of China (82273352), the Youth Incubation Project of Xian Health Commission (2024qn01), Scientific Research Foundation of Hangzhou City College (X-202305), National College Student Innovation and Entrepreneurship Project (202313021036), and Zhejiang Provincial Medical and Health Technology Project (2025KY391).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguirre-Gamboa</surname><given-names>R</given-names></name><name><surname>Gomez-Rueda</surname><given-names>H</given-names></name><name><surname>Martínez-Ledesma</surname><given-names>E</given-names></name><name><surname>Martínez-Torteya</surname><given-names>A</given-names></name><name><surname>Chacolla-Huaringa</surname><given-names>R</given-names></name><name><surname>Rodriguez-Barrientos</surname><given-names>A</given-names></name><name><surname>Tamez-Peña</surname><given-names>JG</given-names></name><name><surname>Treviño</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e74250</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0074250</pub-id><pub-id pub-id-type="pmid">24066126</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alduais</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Fan</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Non-small cell lung cancer (NSCLC): a review of risk factors, diagnosis, and treatment</article-title><source>Medicine</source><volume>102</volume><elocation-id>e32899</elocation-id><pub-id pub-id-type="doi">10.1097/MD.0000000000032899</pub-id><pub-id pub-id-type="pmid">36827002</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baillie</surname><given-names>GS</given-names></name><name><surname>Tejeda</surname><given-names>GS</given-names></name><name><surname>Kelly</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Therapeutic targeting of 3’,5’-cyclic nucleotide phosphodiesterases: inhibition and beyond</article-title><source>Nature Reviews. Drug Discovery</source><volume>18</volume><fpage>770</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1038/s41573-019-0033-4</pub-id><pub-id pub-id-type="pmid">31388135</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartha</surname><given-names>Á</given-names></name><name><surname>Győrffy</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>TNMplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues</article-title><source>International Journal of Molecular Sciences</source><volume>22</volume><elocation-id>2622</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22052622</pub-id><pub-id pub-id-type="pmid">33807717</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Dogrusoz</surname><given-names>U</given-names></name><name><surname>Gross</surname><given-names>BE</given-names></name><name><surname>Sumer</surname><given-names>SO</given-names></name><name><surname>Aksoy</surname><given-names>BA</given-names></name><name><surname>Jacobsen</surname><given-names>A</given-names></name><name><surname>Byrne</surname><given-names>CJ</given-names></name><name><surname>Heuer</surname><given-names>ML</given-names></name><name><surname>Larsson</surname><given-names>E</given-names></name><name><surname>Antipin</surname><given-names>Y</given-names></name><name><surname>Reva</surname><given-names>B</given-names></name><name><surname>Goldberg</surname><given-names>AP</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data</article-title><source>Cancer Discovery</source><volume>2</volume><fpage>401</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0095</pub-id><pub-id pub-id-type="pmid">22588877</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandrashekar</surname><given-names>DS</given-names></name><name><surname>Bashel</surname><given-names>B</given-names></name><name><surname>Balasubramanya</surname><given-names>SAH</given-names></name><name><surname>Creighton</surname><given-names>CJ</given-names></name><name><surname>Ponce-Rodriguez</surname><given-names>I</given-names></name><name><surname>Chakravarthi</surname><given-names>BVSK</given-names></name><name><surname>Varambally</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses</article-title><source>Neoplasia</source><volume>19</volume><fpage>649</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1016/j.neo.2017.05.002</pub-id><pub-id pub-id-type="pmid">28732212</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Yan</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>An update of cyclic nucleotide phosphodiesterase as a target for cardiac diseases</article-title><source>Expert Opinion on Drug Discovery</source><volume>16</volume><fpage>183</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1080/17460441.2020.1821643</pub-id><pub-id pub-id-type="pmid">32957823</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>m6A binding protein YTHDF2 in cancer</article-title><source>Experimental Hematology &amp; Oncology</source><volume>11</volume><elocation-id>21</elocation-id><pub-id pub-id-type="doi">10.1186/s40164-022-00269-y</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chitale</surname><given-names>D</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Taylor</surname><given-names>BS</given-names></name><name><surname>Broderick</surname><given-names>S</given-names></name><name><surname>Brennan</surname><given-names>C</given-names></name><name><surname>Somwar</surname><given-names>R</given-names></name><name><surname>Golas</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Motoi</surname><given-names>N</given-names></name><name><surname>Szoke</surname><given-names>J</given-names></name><name><surname>Reinersman</surname><given-names>JM</given-names></name><name><surname>Major</surname><given-names>J</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Seshan</surname><given-names>VE</given-names></name><name><surname>Zakowski</surname><given-names>MF</given-names></name><name><surname>Rusch</surname><given-names>V</given-names></name><name><surname>Pao</surname><given-names>W</given-names></name><name><surname>Gerald</surname><given-names>W</given-names></name><name><surname>Ladanyi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors</article-title><source>Oncogene</source><volume>28</volume><fpage>2773</fpage><lpage>2783</lpage><pub-id pub-id-type="doi">10.1038/onc.2009.135</pub-id><pub-id pub-id-type="pmid">19525976</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delhaye</surname><given-names>S</given-names></name><name><surname>Bardoni</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders</article-title><source>Molecular Psychiatry</source><volume>26</volume><fpage>4570</fpage><lpage>4582</lpage><pub-id pub-id-type="doi">10.1038/s41380-020-00997-9</pub-id><pub-id pub-id-type="pmid">33414502</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixit</surname><given-names>D</given-names></name><name><surname>Prager</surname><given-names>BC</given-names></name><name><surname>Gimple</surname><given-names>RC</given-names></name><name><surname>Poh</surname><given-names>HX</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Qiu</surname><given-names>Z</given-names></name><name><surname>Kidwell</surname><given-names>RL</given-names></name><name><surname>Kim</surname><given-names>LJY</given-names></name><name><surname>Xie</surname><given-names>Q</given-names></name><name><surname>Vitting-Seerup</surname><given-names>K</given-names></name><name><surname>Bhargava</surname><given-names>S</given-names></name><name><surname>Dong</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Hamerlik</surname><given-names>P</given-names></name><name><surname>Jaffrey</surname><given-names>SR</given-names></name><name><surname>Zhao</surname><given-names>JC</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Rich</surname><given-names>JN</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The RNA m6A reader YTHDF2 maintains oncogene expression and is a targetable dependency in glioblastoma stem cells</article-title><source>Cancer Discovery</source><volume>11</volume><fpage>480</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-20-0331</pub-id><pub-id pub-id-type="pmid">33023892</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Aksoy</surname><given-names>BA</given-names></name><name><surname>Dogrusoz</surname><given-names>U</given-names></name><name><surname>Dresdner</surname><given-names>G</given-names></name><name><surname>Gross</surname><given-names>B</given-names></name><name><surname>Sumer</surname><given-names>SO</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Jacobsen</surname><given-names>A</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name><name><surname>Larsson</surname><given-names>E</given-names></name><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal</article-title><source>Science Signaling</source><volume>6</volume><elocation-id>l1</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2004088</pub-id><pub-id pub-id-type="pmid">23550210</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goswami</surname><given-names>CP</given-names></name><name><surname>Nakshatri</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>PROGgeneV2: enhancements on the existing database</article-title><source>BMC Cancer</source><volume>14</volume><elocation-id>970</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2407-14-970</pub-id><pub-id pub-id-type="pmid">25518851</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Q-F</given-names></name><name><surname>Li</surname><given-names>W-J</given-names></name><name><surname>Hu</surname><given-names>K-S</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Zhai</surname><given-names>W-L</given-names></name><name><surname>Yang</surname><given-names>J-H</given-names></name><name><surname>Zhang</surname><given-names>S-J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer</article-title><source>Molecular Cancer</source><volume>21</volume><elocation-id>207</elocation-id><pub-id pub-id-type="doi">10.1186/s12943-022-01671-0</pub-id><pub-id pub-id-type="pmid">36320056</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsien Lai</surname><given-names>S</given-names></name><name><surname>Zervoudakis</surname><given-names>G</given-names></name><name><surname>Chou</surname><given-names>J</given-names></name><name><surname>Gurney</surname><given-names>ME</given-names></name><name><surname>Quesnelle</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>PDE4 subtypes in cancer</article-title><source>Oncogene</source><volume>39</volume><fpage>3791</fpage><lpage>3802</lpage><pub-id pub-id-type="doi">10.1038/s41388-020-1258-8</pub-id><pub-id pub-id-type="pmid">32203163</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Z-Y</given-names></name><name><surname>Wu</surname><given-names>L-W</given-names></name><name><surname>Zeng</surname><given-names>L-H</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>H-J</given-names></name><name><surname>Zhang</surname><given-names>J-K</given-names></name><name><surname>Shao</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Y-L</given-names></name><name><surname>Lin</surname><given-names>N-M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A natural anthraquinone derivative shikonin synergizes with AZD9291 against wtEGFR NSCLC cells through reactive oxygen species-mediated endoplasmic reticulum stress</article-title><source>Phytomedicine</source><volume>68</volume><elocation-id>153189</elocation-id><pub-id pub-id-type="doi">10.1016/j.phymed.2020.153189</pub-id><pub-id pub-id-type="pmid">32070867</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Sundquist</surname><given-names>J</given-names></name><name><surname>Sundquist</surname><given-names>K</given-names></name><name><surname>Ji</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Phosphodiesterase-5 inhibitors use and risk for mortality and metastases among male patients with colorectal cancer</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>3191</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-17028-4</pub-id><pub-id pub-id-type="pmid">32581298</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kakkar</surname><given-names>R</given-names></name><name><surname>Raju</surname><given-names>RV</given-names></name><name><surname>Sharma</surname><given-names>RK</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1)</article-title><source>Cellular and Molecular Life Sciences</source><volume>55</volume><fpage>1164</fpage><lpage>1186</lpage><pub-id pub-id-type="doi">10.1007/s000180050364</pub-id><pub-id pub-id-type="pmid">10442095</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Sheng</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Sheng</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>RNA m<sup>6</sup>A reader YTHDF2 facilitates lung adenocarcinoma cell proliferation and metastasis by targeting the AXIN1/Wnt/β-catenin signaling</article-title><source>Cell Death &amp; Disease</source><volume>12</volume><elocation-id>479</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-021-03763-z</pub-id><pub-id pub-id-type="pmid">33980824</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Miao</surname><given-names>J</given-names></name><name><surname>Jia</surname><given-names>Y</given-names></name><name><surname>Kong</surname><given-names>G</given-names></name><name><surname>Hong</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Zhai</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>N6-methyladenosine reader YTHDF2 promotes multiple myeloma cell proliferation through EGR1/p21<sup>cip1/waf1</sup>/CDK2-Cyclin E1 axis-mediated cell cycle transition</article-title><source>Oncogene</source><volume>42</volume><fpage>1607</fpage><lpage>1619</lpage><pub-id pub-id-type="doi">10.1038/s41388-023-02675-w</pub-id><pub-id pub-id-type="pmid">37012388</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Duan</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Barr</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Bissonnette</surname><given-names>MB</given-names></name><name><surname>Kortylewski</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Caligiuri</surname><given-names>MA</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8<sup>+</sup> T cells</article-title><source>Nature Immunology</source><volume>24</volume><fpage>255</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1038/s41590-022-01398-6</pub-id><pub-id pub-id-type="pmid">36658237</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Messenger</surname><given-names>SW</given-names></name><name><surname>Woo</surname><given-names>SS</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Martin</surname><given-names>TFJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A Ca<sup>2+</sup>-stimulated exosome release pathway in cancer cells is regulated by Munc13-4</article-title><source>The Journal of Cell Biology</source><volume>217</volume><fpage>2877</fpage><lpage>2890</lpage><pub-id pub-id-type="doi">10.1083/jcb.201710132</pub-id><pub-id pub-id-type="pmid">29930202</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohrherr</surname><given-names>J</given-names></name><name><surname>Uras</surname><given-names>IZ</given-names></name><name><surname>Moll</surname><given-names>HP</given-names></name><name><surname>Casanova</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>STAT3: versatile functions in non-small cell lung cancer</article-title><source>Cancers</source><volume>12</volume><elocation-id>1107</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12051107</pub-id><pub-id pub-id-type="pmid">32365499</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muppirala</surname><given-names>UK</given-names></name><name><surname>Honavar</surname><given-names>VG</given-names></name><name><surname>Dobbs</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Predicting RNA-protein interactions using only sequence information</article-title><source>BMC Bioinformatics</source><volume>12</volume><elocation-id>489</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-12-489</pub-id><pub-id pub-id-type="pmid">22192482</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onn</surname><given-names>A</given-names></name><name><surname>Herbst</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Angiogenesis, metastasis, and lung cancer: an overview</article-title><source>Methods in Molecular Medicine</source><volume>74</volume><fpage>329</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1385/1-59259-323-2:329</pub-id><pub-id pub-id-type="pmid">12415706</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>T</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Tong</surname><given-names>R</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Bai</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Inhibitors of phosphodiesterase as cancer therapeutics</article-title><source>European Journal of Medicinal Chemistry</source><volume>150</volume><fpage>742</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2018.03.046</pub-id><pub-id pub-id-type="pmid">29574203</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rousseaux</surname><given-names>S</given-names></name><name><surname>Debernardi</surname><given-names>A</given-names></name><name><surname>Jacquiau</surname><given-names>B</given-names></name><name><surname>Vitte</surname><given-names>A-L</given-names></name><name><surname>Vesin</surname><given-names>A</given-names></name><name><surname>Nagy-Mignotte</surname><given-names>H</given-names></name><name><surname>Moro-Sibilot</surname><given-names>D</given-names></name><name><surname>Brichon</surname><given-names>P-Y</given-names></name><name><surname>Lantuejoul</surname><given-names>S</given-names></name><name><surname>Hainaut</surname><given-names>P</given-names></name><name><surname>Laffaire</surname><given-names>J</given-names></name><name><surname>de Reyniès</surname><given-names>A</given-names></name><name><surname>Beer</surname><given-names>DG</given-names></name><name><surname>Timsit</surname><given-names>J-F</given-names></name><name><surname>Brambilla</surname><given-names>C</given-names></name><name><surname>Brambilla</surname><given-names>E</given-names></name><name><surname>Khochbin</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers</article-title><source>Science Translational Medicine</source><volume>5</volume><elocation-id>186ra66</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3005723</pub-id><pub-id pub-id-type="pmid">23698379</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samidurai</surname><given-names>A</given-names></name><name><surname>Xi</surname><given-names>L</given-names></name><name><surname>Das</surname><given-names>A</given-names></name><name><surname>Iness</surname><given-names>AN</given-names></name><name><surname>Vigneshwar</surname><given-names>NG</given-names></name><name><surname>Li</surname><given-names>P-L</given-names></name><name><surname>Singla</surname><given-names>DK</given-names></name><name><surname>Muniyan</surname><given-names>S</given-names></name><name><surname>Batra</surname><given-names>SK</given-names></name><name><surname>Kukreja</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities</article-title><source>Pharmacology &amp; Therapeutics</source><volume>226</volume><elocation-id>107858</elocation-id><pub-id pub-id-type="doi">10.1016/j.pharmthera.2021.107858</pub-id><pub-id pub-id-type="pmid">33895190</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>B</given-names></name><name><surname>Peng</surname><given-names>S</given-names></name><name><surname>Woods</surname><given-names>DM</given-names></name><name><surname>Wistuba</surname><given-names>I</given-names></name><name><surname>Bell</surname><given-names>D</given-names></name><name><surname>El-Naggar</surname><given-names>AK</given-names></name><name><surname>Lai</surname><given-names>SY</given-names></name><name><surname>Johnson</surname><given-names>FM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma</article-title><source>Clinical Cancer Research</source><volume>18</volume><fpage>127</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-1889</pub-id><pub-id pub-id-type="pmid">22090359</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>BS</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Hsu</surname><given-names>PJ</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>YTHDF3 facilitates translation and decay of N<sup>6</sup>-methyladenosine-modified RNA</article-title><source>Cell Research</source><volume>27</volume><fpage>315</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1038/cr.2017.15</pub-id><pub-id pub-id-type="pmid">28106072</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thai</surname><given-names>AA</given-names></name><name><surname>Solomon</surname><given-names>BJ</given-names></name><name><surname>Sequist</surname><given-names>LV</given-names></name><name><surname>Gainor</surname><given-names>JF</given-names></name><name><surname>Heist</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Lung cancer</article-title><source>Lancet</source><volume>398</volume><fpage>535</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00312-3</pub-id><pub-id pub-id-type="pmid">34273294</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhlén</surname><given-names>M</given-names></name><name><surname>Fagerberg</surname><given-names>L</given-names></name><name><surname>Hallström</surname><given-names>BM</given-names></name><name><surname>Lindskog</surname><given-names>C</given-names></name><name><surname>Oksvold</surname><given-names>P</given-names></name><name><surname>Mardinoglu</surname><given-names>A</given-names></name><name><surname>Sivertsson</surname><given-names>Å</given-names></name><name><surname>Kampf</surname><given-names>C</given-names></name><name><surname>Sjöstedt</surname><given-names>E</given-names></name><name><surname>Asplund</surname><given-names>A</given-names></name><name><surname>Olsson</surname><given-names>I</given-names></name><name><surname>Edlund</surname><given-names>K</given-names></name><name><surname>Lundberg</surname><given-names>E</given-names></name><name><surname>Navani</surname><given-names>S</given-names></name><name><surname>Szigyarto</surname><given-names>CA-K</given-names></name><name><surname>Odeberg</surname><given-names>J</given-names></name><name><surname>Djureinovic</surname><given-names>D</given-names></name><name><surname>Takanen</surname><given-names>JO</given-names></name><name><surname>Hober</surname><given-names>S</given-names></name><name><surname>Alm</surname><given-names>T</given-names></name><name><surname>Edqvist</surname><given-names>P-H</given-names></name><name><surname>Berling</surname><given-names>H</given-names></name><name><surname>Tegel</surname><given-names>H</given-names></name><name><surname>Mulder</surname><given-names>J</given-names></name><name><surname>Rockberg</surname><given-names>J</given-names></name><name><surname>Nilsson</surname><given-names>P</given-names></name><name><surname>Schwenk</surname><given-names>JM</given-names></name><name><surname>Hamsten</surname><given-names>M</given-names></name><name><surname>von Feilitzen</surname><given-names>K</given-names></name><name><surname>Forsberg</surname><given-names>M</given-names></name><name><surname>Persson</surname><given-names>L</given-names></name><name><surname>Johansson</surname><given-names>F</given-names></name><name><surname>Zwahlen</surname><given-names>M</given-names></name><name><surname>von Heijne</surname><given-names>G</given-names></name><name><surname>Nielsen</surname><given-names>J</given-names></name><name><surname>Pontén</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Proteomics: tissue-based map of the human proteome</article-title><source>Science</source><volume>347</volume><elocation-id>1260419</elocation-id><pub-id pub-id-type="doi">10.1126/science.1260419</pub-id><pub-id pub-id-type="pmid">25613900</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhlen</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Sjöstedt</surname><given-names>E</given-names></name><name><surname>Fagerberg</surname><given-names>L</given-names></name><name><surname>Bidkhori</surname><given-names>G</given-names></name><name><surname>Benfeitas</surname><given-names>R</given-names></name><name><surname>Arif</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Edfors</surname><given-names>F</given-names></name><name><surname>Sanli</surname><given-names>K</given-names></name><name><surname>von Feilitzen</surname><given-names>K</given-names></name><name><surname>Oksvold</surname><given-names>P</given-names></name><name><surname>Lundberg</surname><given-names>E</given-names></name><name><surname>Hober</surname><given-names>S</given-names></name><name><surname>Nilsson</surname><given-names>P</given-names></name><name><surname>Mattsson</surname><given-names>J</given-names></name><name><surname>Schwenk</surname><given-names>JM</given-names></name><name><surname>Brunnström</surname><given-names>H</given-names></name><name><surname>Glimelius</surname><given-names>B</given-names></name><name><surname>Sjöblom</surname><given-names>T</given-names></name><name><surname>Edqvist</surname><given-names>P-H</given-names></name><name><surname>Djureinovic</surname><given-names>D</given-names></name><name><surname>Micke</surname><given-names>P</given-names></name><name><surname>Lindskog</surname><given-names>C</given-names></name><name><surname>Mardinoglu</surname><given-names>A</given-names></name><name><surname>Ponten</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A pathology atlas of the human cancer transcriptome</article-title><source>Science</source><volume>357</volume><elocation-id>eaan2507</elocation-id><pub-id pub-id-type="doi">10.1126/science.aan2507</pub-id><pub-id pub-id-type="pmid">28818916</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasaikar</surname><given-names>SV</given-names></name><name><surname>Straub</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>LinkedOmics: analyzing multi-omics data within and across 32 cancer types</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>D956</fpage><lpage>D963</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx1090</pub-id><pub-id pub-id-type="pmid">29136207</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>H-W</given-names></name><name><surname>Zhang</surname><given-names>Z-Q</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Niu</surname><given-names>Q-L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Human RECQL5 promotes metastasis and resistance to cisplatin in non-small cell lung cancer</article-title><source>Life Sciences</source><volume>265</volume><elocation-id>118768</elocation-id><pub-id pub-id-type="doi">10.1016/j.lfs.2020.118768</pub-id><pub-id pub-id-type="pmid">33217443</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>T</given-names></name><name><surname>Bao</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>R</given-names></name><name><surname>Zhuyan</surname><given-names>J</given-names></name><name><surname>Zhen</surname><given-names>T</given-names></name><name><surname>Xing</surname><given-names>K</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mechanisms and future of non-small cell lung cancer metastasis</article-title><source>Frontiers in Oncology</source><volume>10</volume><elocation-id>585284</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2020.585284</pub-id><pub-id pub-id-type="pmid">33262947</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.98903.4.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Evans</surname><given-names>Rachel</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>King's College London</institution><country>United Kingdom</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Solid</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>This manuscript provides <bold>valuable</bold> mechanistic insight into NSCLC progression, both in terms of tumour metastasis and the development of chemoresistance. The authors draw upon a range of techniques and assays and the evidence shown is <bold>solid</bold> and has been strengthened by incorporation of suggestions by the two reviewers. The work presented will be of interest to cancer biologists and more broadly to those interested in NSCLC translational studies.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.98903.4.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The manuscript entitled &quot;Phosphodiesterase 1A Physically Interacts with YTHDF2 and Reinforces the Progression of Non-Small Cell Lung Cancer&quot; explores the role of PDE1A in promoting NSCLC progression by binding to the m6A reader YTHDF2 and regulating the mRNA stability of several novel target genes, consequently activating the STAT3 pathway and leading to metastasis and drug resistance.</p><p>Strengths:</p><p>The study addresses a novel mechanism involving PDE1A and YTHDF2 interaction in NSCLC, contributing to our understanding of cancer progression.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.98903.4.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This revised manuscript investigates the role and the mechanism by which PDE1 impacts NSCLC progression, providing solid data to demonstrate that PDE1 binds to m6A reader YTHDF2, in turn, regulating STAT3 signaling pathway through its interaction, promoting metastasis and angiogenesis. The study provides a valuable information to lung cancer field.</p><p>Strength:</p><p>The study uncovers a novel PDE1A/YTHDF2/SOCS2/STAT3 pathway in NSCLC progression and the findings provide a potential treatment strategy for NSCLC patients with metastasis.</p><p>Weakness:</p><p>Given that physical interaction of PDE1A and YTHDF2 plays a critical role in PDE1A-mediated NSCLC metastasis, the in vivo data to show that YTHDF2 mimics the effect of PDE1A in metastasis will strength the manuscript although this point was mentioned in the revised manuscript.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.98903.4.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Chong</given-names></name><role specific-use="author">Author</role><aff><institution>Shangyu People's Hospital of Shaoxing</institution><addr-line><named-content content-type="city">Hangzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Zuoyan</given-names></name><role specific-use="author">Author</role><aff><institution>Hangzhou City University</institution><addr-line><named-content content-type="city">Hangzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Yueyi</given-names></name><role specific-use="author">Author</role><aff><institution>Hangzhou City University</institution><addr-line><named-content content-type="city">Hangzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Yuchen</given-names></name><role specific-use="author">Author</role><aff><institution>Wenzhou Medical University</institution><addr-line><named-content content-type="city">Wenzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Jing</given-names></name><role specific-use="author">Author</role><aff><institution>Hangzhou City University</institution><addr-line><named-content content-type="city">Hangzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Kaizhi</given-names></name><role specific-use="author">Author</role><aff><institution>Hangzhou City University</institution><addr-line><named-content content-type="city">Hangzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Zhidi</given-names></name><role specific-use="author">Author</role><aff><institution>Hangzhou City University</institution><addr-line><named-content content-type="city">Hangzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Manman</given-names></name><role specific-use="author">Author</role><aff><institution>Hangzhou City University</institution><addr-line><named-content content-type="city">Hangzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jian</given-names></name><role specific-use="author">Author</role><aff><institution>Shangyu People's Hospital of Shaoxing</institution><addr-line><named-content content-type="city">Shaoxing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Xuesen</given-names></name><role specific-use="author">Author</role><aff><institution>Hangzhou Lin'an Traditional Chinese Medicine Hospital</institution><addr-line><named-content content-type="city">Hangzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yangling</given-names></name><role specific-use="author">Author</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05pwsw714</institution-id><institution>Hangzhou First People's Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Hangzhou</named-content></addr-line><country>China</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the previous reviews</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public review):</bold></p><p>Summary:</p><p>The manuscript entitled &quot;Phosphodiesterase 1A Physically Interacts with YTHDF2 and Reinforces the Progression of Non-Small Cell Lung Cancer&quot; explores the role of PDE1A in promoting NSCLC progression by binding to the m6A reader YTHDF2 and regulating the mRNA stability of several novel target genes, consequently activating the STAT3 pathway and leading to metastasis and drug resistance.</p><p>Strengths:</p><p>The study addresses a novel mechanism involving PDE1A and YTHDF2 interaction in NSCLC, contributing to our understanding of cancer progression.</p><p><bold>Reviewer #2 (Public review):</bold></p><p>Summary</p><p>This revised manuscript investigates the role and the mechanism by which PDE1 impacts NSCLC progression. They provide evidence to demonstrate that PDE1 binds to m6A reader YTHDF2, in turn, regulating STAT3 signaling pathway through its interaction, promoting metastasis and angiogenesis.</p><p>Strength:</p><p>The study uncovers a novel PDE1A/YTHDF2/SOCS2/STAT3 pathway in NSCLC progression and the findings provide a potential treatment strategy for NSCLC patients with metastasis.</p><p>Weakness:</p><p>In discussion, it is stated in the revised version that &quot;the role of YTHDF2 in PDE1A-driven tumor metastasis should be elucidated in future studies&quot;, however, given that physical interaction of PDE1A and YTHDF2 plays a critical role in PDE1A-mediated NSCLC metastasis, whether YTHDF2 mimicking the effect of PDE1A in metastasis will strength the manuscript.</p><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>(1) In Figure 1A, the y-axis should be &quot;IOD/Area&quot; instead of &quot;IDO/Area&quot;.</p></disp-quote><p>Figure 1A was revised as suggested.</p><disp-quote content-type="editor-comment"><p>(2) Figure 3A legend for (F) and (G) was switched.</p></disp-quote><p>Figure 3A legend was revised as suggested “(F-G) The mRNA (F) and protein (G) levels of indicated genes were determined in P3 and P0 NSCLC cells.”.</p><disp-quote content-type="editor-comment"><p>(3) The statistical analysis should be performed for Figure 3H.</p></disp-quote><p>Figure 3H was revised as suggested.</p><disp-quote content-type="editor-comment"><p>(4) Figure 4F, Y-axis has a typo for &quot;vessels&quot; and statistical analysis should be performed on this data.</p></disp-quote><p>Figure 4F was revised as suggested.</p><disp-quote content-type="editor-comment"><p>(5) Figure 6 E, typo for &quot;migrated&quot; on the y-axis.</p></disp-quote><p>Figure 6E was revised as suggested.</p><disp-quote content-type="editor-comment"><p>(6) Figure 7 C, typos for &quot;expression&quot; on y-aixs in both figures need to be fixed.</p></disp-quote><p>Figure 7C was revised as suggested.</p><disp-quote content-type="editor-comment"><p>(7) P-values for Figure 7B need to be stated.</p></disp-quote><p>Figure 7B was revised as suggested.</p><disp-quote content-type="editor-comment"><p>(8) m6A should be consistent throughout the manuscript.</p></disp-quote><p>m6A was consistent throughout the manuscript.</p></body></sub-article></article>